MGO One Seven LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX

MGO One Seven LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,603 shares of the company’s stock, valued at approximately $511,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Nilsine Partners LLC acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $1,197,000. Ruffer LLP bought a new stake in Neurocrine Biosciences during the 4th quarter valued at approximately $2,479,000. Korea Investment CORP boosted its stake in Neurocrine Biosciences by 94.3% during the 3rd quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock valued at $10,064,000 after purchasing an additional 34,800 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Neurocrine Biosciences by 17,250.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock valued at $1,120,000 after buying an additional 7,935 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC increased its position in Neurocrine Biosciences by 152.5% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 13,263 shares of the company’s stock worth $1,945,000 after buying an additional 8,011 shares during the period. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 3,810 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $155.01, for a total transaction of $590,588.10. Following the completion of the transaction, the director owned 2,429 shares in the company, valued at $376,519.29. This trade represents a 61.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by company insiders.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $159.05 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $117.40 and a 52-week high of $162.39. The firm has a market capitalization of $15.99 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 1.21 and a beta of 0.34. The company’s fifty day moving average price is $133.55 and its two-hundred day moving average price is $138.32.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a return on equity of 19.79% and a net margin of 21.55%.Neurocrine Biosciences’s revenue was up 28.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.69 earnings per share. Analysts predict that Neurocrine Biosciences, Inc. will post 7.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NBIX has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a report on Monday, April 6th. UBS Group dropped their target price on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Canaccord Genuity Group upped their price objective on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Morgan Stanley lifted their target price on Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Wedbush boosted their price target on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $184.15.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.